1Jones PA,Baylin SB.The epigenomics of cancer[J].Cell,2007,128:683.
2Silverman LR,Holland JF,Weinberg RS,et al.Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes[J].Leukemia,1993,7 Suppl 1:21.
3Silverman LR,McKenzie DR,Peterson BL,et al.Response rates in patients with acute myeloid leukemia,treated with azacytidine,using WHO and intenrational working group criteria for myelodysplastic syndrome[J].Blood,2005,106:525a.
4Silverman LR,Demakos EP,Peterson BL,et al.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancer and leukemia group B[J].J Clin Oncol,2002,20:2429.
5Silverman LR,McKenzie DR,Peterson BL,et al.Further analysis of trials with azacitidine in patients with myelodysplastic syndrome:studies 8421,8921,and 9221 by the Cancer and Leukemia Group B[J].J Clin Oncol,2006,24:2895.
6Fenaux P,Mufti G,Santini V,et al.Azacitidine treatment prolongs overall survival in higher risk MDS patients compared with conventional care regimens:results of the AZA-001 phase III study[J].Blood,2007,110:250a.
7Kaminskas E,Farrell A,Abraham S,et al.Approval summary:azacitidine for treatment of myelodysplastic syndrome subtypes[J].Clin Cancer Res,2005,11:3604.
8Gore SD.Intravenous azacitidine for MDS[J].Clin Adv Hematol Oncol,2007,5:234.
9Lyons R,Cosgriff T,Modi S,et al.Azacytidine(Vidaza) treatment response assessed using three alternative dosing schedules in patients with myelodysplastic syndromes[J].Blood,2005,106:707a.
10Rossetti J,Falke E,Shadduck R,et al.G-CSF increases hematological responses among patients with myelodysplasia treated with azacitidine[J].Blood,2006,108:303b.
